Get the Stockscreener App
0.56
5.26%
-0.0311
Pre-market:
.56
Pasithea Therapeutics Corp stock is traded at $0.56, with a volume of 494.23K.
It is down -5.26% in the last 24 hours and down -28.21% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
See More
Previous Close:
$0.5911
Open:
$0.577
24h Volume:
494.23K
Relative Volume:
1.00
Market Cap:
$18.71M
Revenue:
-
Net Income/Loss:
$-19.73M
P/E Ratio:
-0.27
EPS:
-2.0742
Net Cash Flow:
$-16.94M
1W Performance:
-2.71%
1M Performance:
-28.21%
6M Performance:
-51.72%
1Y Performance:
-28.75%
1-Day Range:
$0.535
$0.60
1-Week Range:
$0.535
$0.6121
52-Week Range:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.56 | 18.71M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times
Pasithea Therapeutics (KTTA) could find a support soon, here's why you should buy the stock now - MSN
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEPS Consistency Score - newsline.com
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Operational Efficiency ImprovesUpward Estimate Revision - newsline.com
PASITHEA THERAPEUTICS CORP (KTTA) Stock Chart - ChartMill
Why Is Pasithea Therapeutics Corp. (KTTAW) Stock Down Today? - Meyka
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis - Investing News Network
Pasithea receives orphan drug status for ALS treatment candidate - Investing.com
Pasithea receives orphan drug status for ALS treatment candidate By Investing.com - Investing.com South Africa
FDA grants rare-disease status to Pasithea ALS drug PAS-004 - Stock Titan
Pasithea Therapeutics (KTTA) Slips 3% as Shares Test Key Support Near $0.64Bollinger Squeeze - newsline.com
KTTA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Surprise History - The Legal Advocate
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Sahm
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Significant EPS Beat Despite Zero RevenueHigh Interest Stocks - Newser
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock SlipsPost-Announcement Reaction - thelegaladvocate.com
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained - TipRanks
Pasithea Therapeutics (KTTA) Stalls at $0.78 — Breakout or Breakdown? 2026-05-18Collar Trade - newsline.com
Pasithea Therapeutics Corp.Common Stock (NQ: KTTA - The Chronicle-Journal
Pasithea Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. 1Q 2026: Net loss $(2.87M), EPS $(0.12) — 10-Q Summary - TradingView
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pasithea Therapeutics (NASDAQ: KTTA) ramps PAS-004 R&D on $50M cash base - Stock Titan
Ameriprise (KTTA) reports 1.35M-share, 5.4% stake in Pasithea Therapeutics - Stock Titan
TradingKey - TradingKey
Pasithea Therapeutics appoints chief medical officer - MSN
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
8-K: Current report - Moomoo
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):